Recent investigations have focused on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine neurotransmission. While GCGR activators are widely employed for managing type 2 diabetes mellitus, their unexpected impacts on reinforcement